Drug intelligence / Profile preview

darbepoetin alfa biosimilar (BCD-066)

Development stage: Phase 3
Lead developer: Biocad
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

BCD-066 is a biosimilar of darbepoetin alfa developed by Biocad for the treatment of anemia, particularly in patients with chronic kidney disease and those undergoing chemotherapy for cancer. Darbepoetin alfa is a recombinant erythropoietin that stimulates erythropoiesis by acting as an agonist at the erythropoietin receptor, leading to increased production of red blood cells in the bone marrow. Clinical studies have demonstrated pharmacokinetic and pharmacodynamic equivalence between BCD-066 and the reference product Aranesp (Amgen). The drug has completed Phase III clinical trials in Russia for anemia associated with chronic kidney disease and oncology indications[1][2][3][4][5].

Other names: darbepoetin α biosimilar - Biocad

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on darbepoetin alfa biosimilar (BCD-066).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on darbepoetin alfa biosimilar (BCD-066).

Explore the full profile